Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

CLLS EPS (Diluted)

Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.

Cellectis S.A.NASDAQ: CLLS

EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026

EPS (Diluted) remains negative

Q1 FY2026 EPS (Diluted) was -$0.18, compared with -$0.18 a year earlier. Trailing-twelve-month EPS (Diluted) was -$0.68.

Context

  • EPS (Diluted) grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EPS (Diluted) reaches the consensus estimate from 1 analysts of -$1.21 (-78.1%) for the fiscal year ending Dec 2026, a slowdown from the -65.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.18+33.3% QoQ
Last fiscal yearDec 2025
-$0.68-65.9% YoY
LTMMar 2026
-$0.68-8.4% YoY
EPS (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%-9.6%-9.6 pp
1 year-65.9%-78.1%-12.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Diluted) history

USD · from the income statement

Latest · FY2025
(0.68) USD
Year-over-year change
-65.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Diluted) vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -8.4% is the 5th highest of 10, against a peer median of -23.7%.
CLLS Competitors
EPS (Diluted) for CLLS and competitors
Company Period LTM YoY 3-year CAGR
MREOMereo BioPharma Group plcLTM Mar 2026-$0.22 USD+99.9%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$0.46 USD+52.9%—
ACIUAC Immune S.A.LTM Mar 2026-CHF 0.66 CHF-26.9%—
DRTSAlpha Tau Medical Ltd.LTM Mar 2026-$0.67 USD-42.8%—
CLLSCellectis S.A.LTM Mar 2026-$0.68 USD-8.4%—
AMRNAmarin Corporation plcLTM Mar 2026-$1.62 USD+62.1%—
DBVTDBV Technologies S.A.LTM Mar 2026-$1.93 USD-63.6%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026-$2.1 USD-40.9%—
ANROAlto Neuroscience, Inc.LTM Mar 2026-$2.48 USD-6.4%—
SLNSilence Therapeutics plcLTM Mar 2026-$4.32 USD——
KRROKorro Bio, Inc.LTM Mar 2026-$11.68 USD-23.7%—
Peer median (excluding CLLS) —-23.7%—

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.